Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor.
The not-catchily titled QVA149 is a treatment delivered through an inhaler, mainly targeted at chronic obstructive pulmonary disease - a condition often seen in smokers, or people working in a polluted environment, which can cause debilitating bouts of breathlessness.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Napoleon’s bicorne headgear, the original MAGA hat, could fetch €800,000Collectables Napoleon would not be out of place in Trump’s America, says Chris Carter
-
'We face a £6m inheritance tax bill under Reeves's changes – it's sheer terror'Thousands of families fear they’ll have no option but to look at selling their firms in a fire sale to pay inheritance tax bills, due to Rachel Reeves’s changes to business property relief
